News | April 15, 2009

SCCT Urges Physicians to Use Appropriate Modalities for MPI

SCCT Urges Physicians to Use Appropriate Modalities for MPI

April 15, 2009 - The results of the Detection of Ischemia in Asymptomatic Diabetes (DIAD) study, released in today’s Journal of the American Medical Association (JAMA), found that myocardial perfusion imaging (MPI) screening for coronary artery disease (CAD) in asymptomatic patients with type 2 diabetes did not result in a significant reduction in the rate of heart attacks and death compared to patients who were not screened.

In the DIAD trial, which included 1,123 participants with type 2 diabetes and no symptoms of CAD, patients were randomly assigned to be screened (n=561) for CAD using MPI, or not to be screened (n=562). The average follow-up was 4.8 years, and researchers found that when analyzed according to randomization, there were 15 events in the screening group vs. 17 events in the no-screening group. Of those in the screened group, 409 participants with normal results and 50 with small MPI defects had lower cardiac event rates than the 33 with moderate or large MPI defects. Coronary angiography was performed within 120 days after screening in 4.4% of the screened group. By comparison, only three of the patients in the no-screening group underwent angiography within 120 days after randomization. As the authors note, these figures do not support MPI as being a good screening test for asymptomatic CAD in diabetic patients.

“The problem with screening diabetics with MPI is that this test detects coronary arteries with enough plaque in the arteries that blood flow is restricted. A large proportion of diabetic patients don’t have any plaque buildup in their arteries,” said cardiac imager, Daniel S. Berman, M.D., SCCT president and chief of cardiac imaging and nuclear cardiology at Cedars-Sinai Medical Center. “The use of coronary calcium scanning, a less expensive procedure that can detect the earliest stages of disease, offers a tool to select the patients who might benefit from the MPI procedure.”

CAD is the leading cause of death in individuals with type 2 diabetes. MPI can be an excellent diagnostic tool in symptomatic patients, but is not appropriate for assessing the plaque burden, which would be the most likely cause of myocardial infarction in the asymptomatic patient. Coronary calcium scoring clearly and accurately identifies the risk in an asymptomatic patient, as reported by Detrano et al in “Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups,” published in The New England Journal of Medicine, March 27, 2008. Detrano et al found that “The coronary calcium score is a strong predictor of incident coronary heart disease and provides predictive information beyond that provided by standard risk factors.” (New England Journal of Medicine, 2008; 358:1,336-1,345.)

For more information: www.SCCT.org

Related Content

Coreline Soft Introduces AI Lung Segmentation Solution at RSNA 2018
News | Lung Cancer | December 10, 2018
December 10, 2018 — Korean image software company Coreline Soft Co. Ltd.
FDA Approves New Features for Planmed Verity Cone Beam CT Scanner
Technology | Computed Tomography (CT) | December 07, 2018
The U.S. Food and Drug Administration (FDA) issued an approval letter for the new features and intended uses of the...
YITU Releases AI-Based Cancer Screening Solutions at RSNA 2018
News | Artificial Intelligence | December 06, 2018
Chinese artificial intelligence (AI) healthcare company YITU healthcare released two brand-new products, Intelligent...
Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
GE Healthcare Unveils New Applications and Smart Devices Built on Edison Platform
Technology | Artificial Intelligence | December 05, 2018
GE Healthcare recently announced new applications and smart devices built on Edison – a platform that helps accelerate...
Infervision Introduces AI Capabilities for Chest CT Reading
Technology | Computer-Aided Detection Software | November 30, 2018
Big data and artificial intelligence (AI) company Infervision announced the launch of InferRead CT Chest, a new product...
NeuroLogica and MaxQ AI Announce Distribution Agreement
News | Stroke | November 30, 2018
Clinical diagnostics intelligence platform company MaxQ AI and Samsung NeuroLogica announced a distribution agreement...
Videos | Advanced Visualization | November 30, 2018
This is an example of the FDA-cleared OpenSight augmented reality (AR) system for surgical planning from NovaRad at t